CXCL12 and glioblastoma: Furthermore, Alisertib treatment (48 h, 5 nM) abrogates the expression of CDC42 in CXCL12-stimulated GBM cells (U87MG: 1.9 fold, GBM1: 1.7 fold) (Fig. 5d).